Share Email Print

Journal of Medical Imaging

Investigation of x-ray spectra for iodinated contrast-enhanced dedicated breast CT
Author(s): Stephen J. Glick; Andrey V. Makeev
Format Member Price Non-Member Price
PDF $20.00 $25.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Screening for breast cancer with mammography has been very successful, resulting in part to a reduction of breast cancer mortality by approximately 39% since 1990. However, mammography still has limitations in performance, especially for women with dense breast tissue. Iodinated contrast-enhanced, dedicated breast CT (BCT) has been proposed to improve lesion analysis and the accuracy of diagnostic workup for patients suspected of having breast cancer. A mathematical analysis to explore the use of various x-ray filters for iodinated contrast-enhanced BCT is presented. To assess task-based performance, the ideal linear observer signal-to-noise ratio (SNR) is used as a figure-of-merit under the assumptions of a linear, shift-invariant imaging system. To estimate signal and noise propagation through the BCT detector, a parallel-cascade model was used. The lesion model was embedded into a structured background and included a realistic level of iodine uptake. SNR was computed for 84,000 different exposure settings by varying the kV setting, x-ray filter materials and thickness, breast size, and composition and radiation dose. It is shown that some x-ray filter material/thickness combinations can provide up to 75% improvement in the linear ideal observer SNR over a conventionally used x-ray filter for BCT. This improvement in SNR can be traded off for substantial reductions in mean glandular dose.

Paper Details

Date Published: 26 January 2017
PDF: 10 pages
J. Med. Imag. 4(1) 013504 doi: 10.1117/1.JMI.4.1.013504
Published in: Journal of Medical Imaging Volume 4, Issue 1
Show Author Affiliations
Stephen J. Glick, U.S. Food and Drug Administration (United States)
Andrey V. Makeev, U.S. Food and Drug Administration (United States)

© SPIE. Terms of Use
Back to Top